Emil Skamene

BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.

Emerillon Therapeutics, Inc. used to develop genomics-based drugs for human complex diseases through its unique RCS mouse platform technology, its access to human patient samples, and its expertise in high throughput mutation screening and ion channel genomics. It also offers contract services, such as mutation detection using dHPLC, mouse genotyping, and speed congenesis. The company was founded in January 2003 and is headquartered was Montréal, Canada.

McGill University Health Center provides health care services. The firm offers multidisciplinary patient centric care services. The company was founded in 1997 and is headquartered in Montreal, Canada.

Neurochem (International) Ltd. provides licensing and partnering activities. Its services include supply chain management and sales, clinical, and regulatory & marketing functions required to develop products. Neurochem is headquartered in Lausanne, Switzerland.